Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1811 results
November 2015
-
Media Release
Novartis highlights clinical advances at ASH 2015, underscoring leadership in hematology research
Pivotal overall survival data for investigational compound PKC412 (midostaurin) in adults with newly diagnosed FLT3-mutated acute myeloid leukemia Presentations highlight new CTL019 data in… -
Story Access to Healthcare
Bringing modern medicine to rural Vietnam
Efforts are underway to reinforce health education and healthcare delivery in rural Vietnam to combat a rise in chronic diseases such as diabetes, hypertension and respiratory ailments.
-
Media Release
Novartis' heart failure medicine Entresto(TM) receives EU approval
Decision brings hope of longer and better life with fewer hospitalizations for millions of Europeans with symptomatic chronic heart failure with reduced ejection fraction Entresto is the… -
Media Release
Novartis receives two landmark European approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis
Cosentyx is the first and only IL-17A inhibitor from a new class of medicines shown to treat two of the most common inflammatory joint conditions in Europe[1] Cosentyx shows rapid and… -
Media Release
Novartis Pharmaceuticals Corporation finalizes settlement agreement resolving civil suit filed by the U.S. Attorney's Office for the Southern District of New York
Novartis Pharmaceuticals Corporation (NPC) has agreed to certain provisions relating to specialty pharmacies as part of an addendum to its existing corporate integrity agreement (CIA), which will… -
Media Release
Regulatory submission for Sandoz' proposed biosimilar pegfilgrastim accepted by the FDA
Sandoz continues to advance its biosimilars program: Regulatory submission for Sandoz' proposed biosimilar pegfilgrastim accepted by the FDA Sandoz demonstrates commitment to oncology by seeking… -
Media Release
FLAME study shows superiority of Novartis' Ultibro® Breezhaler® over Seretide® in reducing COPD exacerbations
Ultibro® Breezhaler® met primary endpoint and demonstrated superiority to Seretide® in reducing COPD exacerbations during 52 weeks of treatment First large-scale study to confirm Ultibro… -
Media Release
Alcon introduces Contoura Vision as first personalized LASIK procedure at American Academy of Ophthalmology Annual Meeting
Nearly 65% of eyes treated with personalized topography-guided LASIK experienced 20/16 vision or better[1] in clinical study Alcon is the first refractive laser manufacturer to receive FDA… -
Media Release
Novartis presents new two year data for Cosentyx® showing no progression in joint damage in 84% of psoriatic arthritis patients
New x-ray assessment data, from a sub-study, showed no progression of joint structural damage in the majority of patients with psoriatic arthritis over two years[1] Psoriatic arthritis patients on… -
Media Release
New two year data for Novartis' Cosentyx® show sustained response and no progression in spinal damage as shown by x-ray in up to 80% of patients with ankylosing spondylitis
A sub-study showed up to 80% of ankylosing spondylitis (AS) patients treated with Cosentyx had no radiographic progression in the spine over two years[1] Cosentyx demonstrated a sustained… -
Story From Our Labs
Giraffes have high blood pressure. Why don’t they drop dead?
A certain leggy resident of the African grasslands is arousing a lot of interest among evolutionary biologists. They believe that study of giraffes' unique features could lead the way to advances in human health.